Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FFBN9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,213
Award facts
- Contract value 100% obligated
- $14,212.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $14,212.98 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. The delivery order, issued December 3, 2025, with an ultimate completion date of December 24, 2025, carries firm fixed-price terms and no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a broader $30.3 billion acquisition strategy that positions the company as a regional prime vendor contractor for the Department of Defense.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial contracting activity through the Defense Logistics Agency's Medical Supply Chain division. The company's comprehensive product portfolio includes branded and generic pharmaceuticals, biologics, vaccines, and specialty medical products serving military healthcare facilities. The parent Indefinite Delivery Contract, designated SPE2DR and awarded November 13, 2025, carries a ceiling value of $499,999,999 with performance extending through December 31, 2036, including a 30-month base period and three optional 30-month extension periods. This delivery order represents one of numerous firm fixed-price orders the agency continues to issue for diverse pharmaceutical requirements supporting Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FFBN9?
SPE2DR26FFBN9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FFBN9 worth?
The government has obligated $14,213 on SPE2DR26FFBN9.
Is contract SPE2DR26FFBN9 an order under another contract?
Yes. SPE2DR26FFBN9 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBN9 competed?
The extent of competition for SPE2DR26FFBN9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award